Isocitrate Dehydrogenase-Mutant WHO Grade 4 Astrocytoma with BCOR Alteration: Case Report

异柠檬酸脱氢酶突变型 WHO 4 级星形细胞瘤伴 BCOR 改变:病例报告

阅读:1

Abstract

INTRODUCTION: BCOR, a transcriptional regulator and component of the noncanonical polycomb repressive complex 1 (PRC1), plays an important role in tumorigenesis through transcriptional repression mediated by histone modifications. Alterations in BCOR, including nonsense, frameshift, and splice site mutations, have been reported in several brain tumors such as glial tumors, astroblastomas, pineoblastomas, and medulloblastomas. However, BCOR alterations have not previously been described in IDH-mutant WHO grade 4 astrocytoma. CASE PRESENTATION: We describe an adult patient who presented with a recurrent, contrast-enhancing tumor in the left parietal region. The patient underwent complete surgical resection, and histopathology confirmed an IDH-mutant WHO grade 4 astrocytoma. Next-generation sequencing was performed using the TruSight Oncology 500 (TSO500) platform, including both DNA and RNA sequencing. Analysis revealed mutations in IDH1, ATRX, and EGFR, as well as a novel BCOR internal tandem duplication (ITD). CONCLUSION: This case represents the first report of a BCOR ITD in an IDH-mutant WHO grade 4 astrocytoma. The discovery expands the molecular spectrum of high-grade astrocytomas and highlights the need for further research into the biological, prognostic, and therapeutic significance of BCOR alterations in these tumors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。